All change on diabetes drug delivery in the EU
This article was originally published in Clinica
Executive Summary
The next few years are likely to see the rise of the reusable pen as the drug delivery method for insulin drugs in the $439 million (in 2000) EU diabetes drug delivery market. A new report from Frost & Sullivan* predicts that Italy, France, Spain and the UK will embrace this sophisticated technology to the detriment of syringes, use of which will decline in the coming six years, and insulin pumps.